Sample sizes for designing bioequivalence studies for highly variable drugs

L. Tóthfalusi, Laszlo Endrenyi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose. To provide tables of sample sizes which are required, by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), for the design of bioequivalence (BE) studies involving highly variable drugs. To elucidate the complicated features of the relationship between sample size and within-subject variation. Methods. 3- and 4-period studies were simulated with various sample sizes. They were evaluated, at various variations and various true ratios of the two geometric means (GMR), by the approaches of scaled average BE and by average BE with expanding limits. The sample sizes required for yielding 80% and 90% statistical powers were determined. Results. Because of the complicated regulatory expectations, the features of the required sample sizes are also complicated. When the true GMR = 1.0 then, without additional constraints, the sample size is independent of the intrasubject variation. When the true GMR is increased or decreased from 1.0 then the required sample sizes rise at above but close to 30% variation. An additional regulatory constraint on the point estimate of GMR and a cap on the use of expanding limits further increase the required sample size at high variations. Fewer subjects are required by the FDA than by the EMA procedures. Conclusions. The methods proposed by EMA and FDA lower the required sample sizes in comparison with unscaled average BE. However, each additional regulatory requirement (applying the mixed procedure, imposing a constraint on the point estimate of GMR, and using a cap on the application of expanding limits) raises the required number of subjects.

Original languageEnglish
Pages (from-to)73-84
Number of pages12
JournalJournal of Pharmacy and Pharmaceutical Sciences
Volume15
Issue number1
Publication statusPublished - Dec 22 2011

Fingerprint

Therapeutic Equivalency
Sample Size
Pharmaceutical Preparations
United States Food and Drug Administration
Drug Design
Food

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Sample sizes for designing bioequivalence studies for highly variable drugs. / Tóthfalusi, L.; Endrenyi, Laszlo.

In: Journal of Pharmacy and Pharmaceutical Sciences, Vol. 15, No. 1, 22.12.2011, p. 73-84.

Research output: Contribution to journalArticle

@article{ea76534af42c45b49cecabca63fab306,
title = "Sample sizes for designing bioequivalence studies for highly variable drugs",
abstract = "Purpose. To provide tables of sample sizes which are required, by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), for the design of bioequivalence (BE) studies involving highly variable drugs. To elucidate the complicated features of the relationship between sample size and within-subject variation. Methods. 3- and 4-period studies were simulated with various sample sizes. They were evaluated, at various variations and various true ratios of the two geometric means (GMR), by the approaches of scaled average BE and by average BE with expanding limits. The sample sizes required for yielding 80{\%} and 90{\%} statistical powers were determined. Results. Because of the complicated regulatory expectations, the features of the required sample sizes are also complicated. When the true GMR = 1.0 then, without additional constraints, the sample size is independent of the intrasubject variation. When the true GMR is increased or decreased from 1.0 then the required sample sizes rise at above but close to 30{\%} variation. An additional regulatory constraint on the point estimate of GMR and a cap on the use of expanding limits further increase the required sample size at high variations. Fewer subjects are required by the FDA than by the EMA procedures. Conclusions. The methods proposed by EMA and FDA lower the required sample sizes in comparison with unscaled average BE. However, each additional regulatory requirement (applying the mixed procedure, imposing a constraint on the point estimate of GMR, and using a cap on the application of expanding limits) raises the required number of subjects.",
author = "L. T{\'o}thfalusi and Laszlo Endrenyi",
year = "2011",
month = "12",
day = "22",
language = "English",
volume = "15",
pages = "73--84",
journal = "Journal of Pharmacy and Pharmaceutical Sciences",
issn = "1482-1826",
publisher = "Canadian Society for Pharmaceutical Sciences",
number = "1",

}

TY - JOUR

T1 - Sample sizes for designing bioequivalence studies for highly variable drugs

AU - Tóthfalusi, L.

AU - Endrenyi, Laszlo

PY - 2011/12/22

Y1 - 2011/12/22

N2 - Purpose. To provide tables of sample sizes which are required, by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), for the design of bioequivalence (BE) studies involving highly variable drugs. To elucidate the complicated features of the relationship between sample size and within-subject variation. Methods. 3- and 4-period studies were simulated with various sample sizes. They were evaluated, at various variations and various true ratios of the two geometric means (GMR), by the approaches of scaled average BE and by average BE with expanding limits. The sample sizes required for yielding 80% and 90% statistical powers were determined. Results. Because of the complicated regulatory expectations, the features of the required sample sizes are also complicated. When the true GMR = 1.0 then, without additional constraints, the sample size is independent of the intrasubject variation. When the true GMR is increased or decreased from 1.0 then the required sample sizes rise at above but close to 30% variation. An additional regulatory constraint on the point estimate of GMR and a cap on the use of expanding limits further increase the required sample size at high variations. Fewer subjects are required by the FDA than by the EMA procedures. Conclusions. The methods proposed by EMA and FDA lower the required sample sizes in comparison with unscaled average BE. However, each additional regulatory requirement (applying the mixed procedure, imposing a constraint on the point estimate of GMR, and using a cap on the application of expanding limits) raises the required number of subjects.

AB - Purpose. To provide tables of sample sizes which are required, by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), for the design of bioequivalence (BE) studies involving highly variable drugs. To elucidate the complicated features of the relationship between sample size and within-subject variation. Methods. 3- and 4-period studies were simulated with various sample sizes. They were evaluated, at various variations and various true ratios of the two geometric means (GMR), by the approaches of scaled average BE and by average BE with expanding limits. The sample sizes required for yielding 80% and 90% statistical powers were determined. Results. Because of the complicated regulatory expectations, the features of the required sample sizes are also complicated. When the true GMR = 1.0 then, without additional constraints, the sample size is independent of the intrasubject variation. When the true GMR is increased or decreased from 1.0 then the required sample sizes rise at above but close to 30% variation. An additional regulatory constraint on the point estimate of GMR and a cap on the use of expanding limits further increase the required sample size at high variations. Fewer subjects are required by the FDA than by the EMA procedures. Conclusions. The methods proposed by EMA and FDA lower the required sample sizes in comparison with unscaled average BE. However, each additional regulatory requirement (applying the mixed procedure, imposing a constraint on the point estimate of GMR, and using a cap on the application of expanding limits) raises the required number of subjects.

UR - http://www.scopus.com/inward/record.url?scp=84856186304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856186304&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 73

EP - 84

JO - Journal of Pharmacy and Pharmaceutical Sciences

JF - Journal of Pharmacy and Pharmaceutical Sciences

SN - 1482-1826

IS - 1

ER -